ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oxycodone

Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.

Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.

Drug pageOxycodone: every studyMany companies study it; this page follows only the 64 they lead. All 209 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 8, 201164 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mundipharmaits history only200 open or runningphase 4since Mar 8, 2011Jul 27, 2007none ahead
Knoa Pharmaits history only120 open or runningphase 3since Apr 6, 2006Apr 6, 2006none ahead
Pain Therapeuticsits history only120 open or runningphase 3since Mar 13, 2012Aug 12, 2008none ahead
Pfizerits history only60 open or runningphase 4since Jun 8, 2007Jun 8, 2007none ahead
Egaletits history only30 open or runningphase 3since Nov 10, 2015Dec 2, 2008none ahead
Keenova Therapeuticsits history only30 open or runningphase 1since Feb 26, 2009Feb 26, 2009none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
biodelivery-sciences-internationalits history only10 open or runningphase 1since Jun 21, 2019Jun 21, 2019none ahead
elite-laboratories-incits history only10 open or runningphase 3since Feb 17, 2015Feb 17, 2015none ahead
gl-pharm-tech-corporationits history only10 open or runningphase 1since Mar 19, 2012Mar 19, 2012none ahead
napp-pharmaceuticals-limited10 open or runningphase 4since Nov 3, 2008Nov 3, 2008none ahead

Also a collaborator on its studies: PRA Health Sciences and Grünenthal.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of napp-pharmaceuticals-limited only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2008First study: phase 4 study in OsteoarthritisFirst studyNCT00784810 · 247 enrolled · United Kingdom

TargetBeta

OPRM1 →read by rule
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRM1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
MethadoneruleMerckphase 416
cebranopadolruleTris Pharmaphase 318
axelopranruleglycyx-therapeuticsphase 28
AlfentanilruleSichuan Kelun Pharmaceuticalphase 11

Studies

The one study napp-pharmaceuticals-limited leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00784810Osteoarthritis · United Kingdom4CompletedMar 2010247

How it is read

Names in the registry

  • “Oxycodone”, 43 entries
  • “Reformulated OXY (oxycodone HCl)”, 6 entries
  • “Oxycodone/Naloxone”, 5 entries
  • “oxycodone hydrochloride”, 4 entries
  • “Oxycodone hydrochloride”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.